Immunotherapy in first-line for advanced non-small cell lung cancer: <br>a cost-effective choice?
The present evaluation was restricted to pivotal phase III randomized controlled trials (RCTs) in first-line for metastatic non-small cell lung cancer (NSCLC). We calculated the pharmacological costs necessary to get the benefit in overall survival (OS), for each trial. Our analysis evaluated 10 phase III RCTs, including 9485 patients. The most relevant increase of cost € per month of OS-gain was associated with bevacizumab (66,720 €) and the lowest with the use of pembrolizumab (2734 €). Combining pharmacological costs of drugs with the measure of efficacy represented by OS, pembrolizumab is a cost-effective first-line treatment for patients with metastatic NSCLC.